Scancell Holdings Plc Identification of 2nd Moditope Cancer Vaccine (5965F)
October 30 2018 - 3:00AM
UK Regulatory
TIDMSCLP
RNS Number : 5965F
Scancell Holdings Plc
30 October 2018
30 October 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Identification of second Moditope(R) cancer vaccine target -
homocitrullination
Basis for development of Modi-2 for multiple solid tumours
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, today announces an update on the
development of its second vaccine from its proprietary Moditope
platform, Modi-2. Pre-clinical data demonstrates that
homocitrullinated peptides induce highly potent T cell responses,
tumour rejection and increased survival in murine models.
Moditope represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTMs) which could have a
profound effect on the way that cancer immunotherapies are
developed. Scancell's lead Moditope vaccine, Modi-1, acts by
stimulating the production of CD4 T cells using citrullinated
tumour-associated peptide epitopes, which overcome self-tolerance
and destroy tumour cells. Modi-2 exploits a new modification,
stimulating the production of CD4 T cells using homocitrullinated
tumour-associated peptide epitopes. Whereas citrullination involves
the conversion of the amino acid arginine to citrulline, the
process of homocitrullination involves the conversion of lysine to
homocitrulline. Scancell believes this second mechanism of action
has the potential to broaden the utilisation of the Moditope
platform.
Modi-2 is currently in pre-clinical development and work is
underway to characterise specific homocitrullinated peptides for
clinical development that have the potential to address different
cancer indications to Modi-1, including tumours with a particularly
immunosuppressive environment. The Modi-2 peptide family is the
subject of new intellectual property applications with a view to
extend the Company's dominant patent position in relation to
post-translational modifications of cellular proteins and their
application in the treatment of cancer.
Prof Lindy Durrant, Chief Scientific Officer of Scancell,
commented: "We are pleased to be able to provide an update on the
progress of our second Moditope vaccine, Modi-2. The data clearly
demonstrates the potential of homocitrullinated, as well as
citrullinated, tumour-associated peptide epitopes to be developed
for the treatment of solid cancers."
Prof. Durrant will provide an overview of Modi-2 and its
potential as a new vaccine for the treatment of cancer at the
Company's AGM today. Her presentation will be available on the
company website, www.scancell.co.uk.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Mo Noonan/Simon Conway +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4+ T cells which overcome the immune suppression induced
by tumours. allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESEAAENALLPFAF
(END) Dow Jones Newswires
October 30, 2018 03:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024